Search - tctmd.com

Displaying 101 - 120 of 165

Sort: Relevancy | Date

News Conference News TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

Shelley Wood

October 20, 2017

News Conference News TCT 2016

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Shelley Wood

November 07, 2016

News Conference News TCT 2016

Final RESPECT Data Support PFO Closure for Cryptogenic Stroke Prevention

Yael L. Maxwell

November 01, 2016

Presentation TCT 2016

Beyond Cells: Cardiac Gene Therapy In Perspective

Presenter: Emerson C. Perin, Marc S. Penn

October 31, 2016

Presentation TCT 2016

Duration of DAPT Therapy With Contemporary DES (Including BVS)

Presenter: Alejandro Cherro, Anibal A. Damonte, Alfredo E. Rodriguez, Gustavo A Samaja

October 31, 2016

News Conference News TCT 2016

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Yael L. Maxwell

October 31, 2016

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

News Conference News TCT 2016

DES With Biodegradable Polymers Stand Up Well Against Durable-Polymer Stents in the Short Term

Todd Neale

October 30, 2016

News Conference News TCT 2016

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

Michael O'Riordan

October 29, 2016

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? No Cell Works. Genes are the Answer.

Presenter: Nabil Dib, Philippe Menasché, Marc S. Penn

October 15, 2015

Presentation TCT 2015

Gene Therapy for CHF

Presenter: Henricus J. Duckers, Bernard J. Gersh, Gary L. Schaer

October 14, 2015

News Conference News TCT 2015

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Todd Neale

October 14, 2015

News Conference News TCT 2015

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Yael L. Maxwell

October 14, 2015

News Conference News TCT 2015

Trial Results Often Struggle to Keep Pace With Evolving Technology

Nicole Lou

October 13, 2015

News Conference News TCT 2015

FDA Speaker Outlines a Novel Vision for Device Regulation

October 13, 2015

News Conference News TCT 2015

Discussion Highlights Merits, Limitations of Small Trials

Yael L. Maxwell

October 13, 2015

News Conference News TCT 2015

CENTURY II: Bioresorbable-Polymer DES Safe, Effective at 2 Years

October 13, 2015

News Conference News TCT 2015

First-in-Human Studies: Novel Devices for Aortic Valve Stenosis Safe, Feasible

October 12, 2015

News Conference News TCT 2015

Endovascular Therapies for Stroke Challenge the Adage ‘Time is Brain’

October 12, 2015

News Conference News TCT 2015

DRAGON: Transradial as Effective as Transfemoral in Ad Hoc PCI, With Less Risk of Bleeding

October 12, 2015

Advertisement

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Final RESPECT Data Support PFO Closure for Cryptogenic Stroke Prevention

Beyond Cells: Cardiac Gene Therapy In Perspective

Duration of DAPT Therapy With Contemporary DES (Including BVS)

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

DES With Biodegradable Polymers Stand Up Well Against Durable-Polymer Stents in the Short Term

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? No Cell Works. Genes are the Answer.

Gene Therapy for CHF

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Trial Results Often Struggle to Keep Pace With Evolving Technology

FDA Speaker Outlines a Novel Vision for Device Regulation

Discussion Highlights Merits, Limitations of Small Trials

CENTURY II: Bioresorbable-Polymer DES Safe, Effective at 2 Years

First-in-Human Studies: Novel Devices for Aortic Valve Stenosis Safe, Feasible

Endovascular Therapies for Stroke Challenge the Adage ‘Time is Brain’

DRAGON: Transradial as Effective as Transfemoral in Ad Hoc PCI, With Less Risk of Bleeding

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content